Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN phase 3 brensocatib study in non-cystic fibrosis bronchiectasis
jRCT2031210048Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of brensocatib in bronchiectasis (3 arms), sponsored by Insmed Incorporated. Primary endpoint: Annualized rate of pulmonary exacerbations. Started Dec 2020; status: completed.
02
Drugs
brensocatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on jRCT2031210048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210048.